Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether the support for travel costs for children and young people with cancer introduced in the National Cancer Plan for England will be for England only or whether support will also be available for those in other nations, who may travel to England for some or all of their care; and whether any Barnett consequentials will arise from this funding.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department knows that the cost of travel is an important issue for many young cancer patients and their families across the United Kingdom.
Through the National Cancer Plan for England, the Government is committing up to £10 million a year to a new fund open to all children and young people in England with cancer and their families regardless of income, to support them with the cost of travelling to and from treatment. This commitment sits alongside wider action to transform cancer care for children and young people. The Department is currently working with its partners to define the scope and parameters of the scheme and further detail will be announced in due course.
Health is predominately devolved. Devolved governments receive funding through the Barnett Formula, and it is ultimately for them to allocate, prioritise, and manage their budgets. This funding is not new and so Barnett consequentials do not apply. However, the Department does work closely with our counterparts in the devolved governments to share expertise and identify new opportunities to improve health and social care delivery across the UK.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to improve targeted case-finding and earlier diagnosis of chronic obstructive pulmonary disease in community settings.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
To enable faster diagnosis of asthma and chronic obstructive pulmonary disease (COPD) and earlier treatment, access to spirometry tests in community diagnostic centres (CDCs) is growing and will continue to do so as more sites come online. The first five months of 2025/26 saw an increase in CDC spirometry testing of approximately 2,000 tests per month more than in the previous year.
As of November 2025, CDCs are now delivering additional tests and checks in 170 sites across the country. 101 CDCs across the country now offer out of hours services, 12 hours a day, seven days a week, meaning patients can access vital diagnostic tests around busy working lives.
Research into new diagostic tests for COPD, such as computed cardiopulmonography and N-Tidal Diagnose, is underway. Discussions on whether new diagnostic pathways could be developed will be dependent on the research findings.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether the National Cancer Board will be accountable for the children and young people’s chapter of the National Cancer Plan for England; and, if so, how it will ensure sufficient representation from the children and young people sector.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Cancer Plan for England, published on the 4 February 2026, sets out several commitments and ambitions, to be delivered within the next 10 years. The role of the reformed National Cancer Board will be to support and monitor the delivery of the commitments and ambitions and provide regular updates to ministers.
The board will be co-chaired by the Director General for Planned Care in the Department, as well as an independent representative. It is important to choose the most suitable appointment process for selecting an independent representative to co-chair the board. Officials from NHS England and the Department are carefully following the required public appointments procedures for the selection of the independent representative.
The reformed National Cancer Board will be established once a co-chair is appointed, which will include a children and young people cancer lead that will support the delivery of the children and young people commitments in the National Cancer Plan.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to enable the adoption of innovative diagnostic technologies for chronic obstructive pulmonary disease within the NHS; and what engagement they have had with clinical bodies to support large-scale implementation of targeted case-finding pathways that promote earlier diagnosis and help prevent disease progression.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service is working to expand access to innovative diagnostic technologies for chronic obstructive pulmonary disease (COPD). Research into new diagnostic tests for COPD, such as computed cardiopulmonography and N-Tidal Diagnose, is underway.
Discussions on whether new diagnostic pathways could be developed will be dependent on the research findings.
NHS England continues to work closely with Respiratory Clinical Networks and bodies such as the British Thoracic Society to support improvements to services.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what discussions they have had with clinicians and relevant professional bodies regarding the development of new diagnostic pathways for chronic obstructive pulmonary disease that reduce reliance on a single test and enable diagnosis in a wider range of care settings.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
To enable faster diagnosis of asthma and chronic obstructive pulmonary disease (COPD) and earlier treatment, access to spirometry tests in community diagnostic centres (CDCs) is growing and will continue to do so as more sites come online. The first five months of 2025/26 saw an increase in CDC spirometry testing of approximately 2,000 tests per month more than in the previous year.
As of November 2025, CDCs are now delivering additional tests and checks in 170 sites across the country. 101 CDCs across the country now offer out of hours services, 12 hours a day, seven days a week, meaning patients can access vital diagnostic tests around busy working lives.
Research into new diagostic tests for COPD, such as computed cardiopulmonography and N-Tidal Diagnose, is underway. Discussions on whether new diagnostic pathways could be developed will be dependent on the research findings.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government when they plan to publish a response to the The Hughes Report: Options for redress for those harmed by valproate and pelvic mesh, published on 7 February 2024; and when they expect redress schemes to be approved for sodium valproate and pelvic mesh.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is carefully considering the valuable work done by the Patient Safety Commissioner and the resulting Hughes Report, which sets out options for redress for those harmed by sodium valproate and pelvic mesh. The Minister for Health Innovation and Patient Safety recently met with the Patient Safety Commissioner to provide an update on the ongoing health initiatives led by the Department regarding sodium valproate and pelvic mesh. Though a decision to provide financial compensation has not yet been made, the Government is determined to make meaningful progress on this area.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what the Department of Health and Social Care and NHS England have spent on work relating to Part IX of the Drug Tariff and the MedTech Commercial Strategy.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Across the Department and NHS England, £1,067,157.34 has been spent directly on Part IX of the Drug Tariff, including VAT where applicable. This does not include Department and NHS England staff time. This covers the period 2024/25, and 2025/26. This includes planned spend up until the end of the 2025/2026 financial year.
For the MedTech Commercial Strategy, across the Department and NHS England, planned direct spend up until the end of the 2025/26 financial year is £120,000. This does not include Department and NHS England staff time and includes VAT.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the recent decisions by countries such as Germany, Sweden, and Norway to incorporate wider societal impacts within their health technology assessment methodologies; and whether Ministers have considered adopting similar approaches in England.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In 2022, the National Institute for Health and Care Excellence (NICE) undertook a detailed appraisal of whether it should broaden the perspective it uses in its economic evaluations, including consideration of wider societal impacts. NICE found that robust methods for quantifying wider societal effects are not yet sufficiently developed, and that evidence on the wider societal benefits of interventions, and of the services that might be displaced, is limited. NICE has also noted that expanding assessments to capture socio‑economic impacts could introduce ethical challenges, such as advantaging interventions for populations with higher workforce participation over those for children, older adults, or people unable to work.
Following this review, and after examining both international comparisons, and the significant methodological and ethical challenges involved, NICE’s Board concluded that it should retain its current approach of using a health-sector perspective routinely but with the flexibility to include wider societal benefits when they are especially relevant.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 29 January (HL13801), whether they plan to collect data on respiratory syncytial virus related hospital admissions of infants under one year old in weekly surveillance reports; if not, for what reason this data is being omitted.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Numbers of respiratory syncytial virus (RSV) admissions in infants are reported by a sentinel network of approximately 15 to 20 National Health Service trusts in England to the Severe Acute Respiratory Infections-Watch Surveillance at the UK Health Security Agency. Participation in this surveillance is completely voluntary for NHS trusts. Therefore, the number of participating trusts can vary from week to week, and comparisons based on simple counts may be misleading.
To provide appropriate context for reported weekly data, weekly admission rates are calculated to monitor trends over time. This uses trust catchment populations published by the Office for Health Improvement and Disparities, which are estimated for under five-year-olds, but which have not been estimated specifically for the under one year old age group, or infants.
Therefore, published rates are based on the available denominator data for the under five-year-olds, and these are publicly available in the national surveillance weekly reports and corresponding datafile at the GOV.UK website.
Further surveillance data and a programme impact assessment will be included in the annual surveillance report on RSV, due to be published in summer 2026. Please refer to the 2024/25 annual surveillance report for a summary of the previous winter season, which is available at the GOV.UK website.
Surveillance reports use hospital admission data and the Office for National Statistics’ mid-year estimates to model catchment populations for hospital trusts. Modelled catchment populations use hospital data, aggregated over three years and resident populations in five-year age bands.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Joint Committee on Vaccination and Immunisation’s (JCVI’s) advice in November 2024 to expand eligibility for the shingles vaccination programme to include people aged 80 and over, what assessment they have made of the impact of delays in implementation on those with comorbidities who are at highest risk of severe shingles disease; what steps they are taking to prioritise protection for these high-risk individuals; and whether they will commit to implementing the JCVI advice before this winter.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Currently, adults become eligible for their shingles vaccination when they turn 65 or 70 years of age, and they remain eligible until their 79th birthday. Adults who are severely immunosuppressed, and therefore most at risk of serious illness and complications from shingles, are eligible from 18 years old and do not have an upper age limit.
The shingles vaccination programme has been in place since 2013, and therefore there will be a significant portion of adults currently aged 80 years old and over who were offered, and received, Zostavax, the previous shingles vaccine. All those who were born after 1 September 1933 would have been offered a vaccine in the programme.
In November 2024, the Joint Committee on Vaccination and Immunisation provided advice to the Government on eligibility for the shingles vaccination programme. This included advice that the Government should consider expanding the shingles vaccination offer to include older adult cohorts aged 80 years old and over. The Government is carefully considering this advice as it sets the policy on who should be offered shingles vaccinations in the future.